The UNC Institutional Biosafety Committee was established to review recombinant DNA research conducted at or sponsored by UNC for compliance with the National Institutes of Health (NIH) guidelines and approve those research projects that are found to conform with the NIH Guidelines. The Institutional Biosafety Committee meets the requirements of the North Carolina Open Meetings Law.

For additional information, e-mail ibc@unc.edu or call Jessica Poole at 919-962-5726.

Committee Mission

On behalf of the institution, the Institutional Biosafety Committee is responsible for:

Reviewing recombinant DNA research conducted at or sponsored by the institution for compliance with the NIH Guidelines as specified in Section III, Experiments Covered by the NIH Guidelines, and approving those research projects that are found to conform with the NIH Guidelines. This review shall include: (i) independent assessment of the containment levels required by the NIH Guidelines for the proposed research; (ii) assessment of the facilities, procedures, practices, and training and expertise of personnel involved in recombinant DNA research; (iii) ensuring that all aspects of Appendix M have been appropriately addressed by the Principal Investigator; (iv) ensuring that no research participant is enrolled (see definition of enrollment in Section I-E-7) in a human gene transfer experiment until the RAC review process has been completed (see Appendix M-I-B, RAC Review Requirements); (v) for human gene transfer protocols selected for public RAC review and discussion, consideration of the issues raised and recommendations made as a result of this review and consideration of the Principal Investigator’s response to the RAC recommendations; (vi) ensuring that final IBC approval is granted only after the RAC review process has been completed (see Appendix M-I-B, RAC Review Requirements); and (vii) ensuring compliance with all surveillance, data reporting, and adverse event reporting requirements set forth in the NIH Guidelines.
Notifying the Principal Investigator of the results of the Institutional Biosafety Committee’s review and approval.
Lowering containment levels for certain experiments as specified in Section III-D-2-a, Experiments in which DNA from Risk Group 2, Risk Group 3, Risk Group 4, or Restricted Agents is Cloned into Nonpathogenic Prokaryotic or Lower Eukaryotic Host-Vector Systems.
Setting containment levels as specified in Sections III-D-4-b, Experiments Involving Whole Animals, and III-D-5, Experiments Involving Whole Plants.
Periodically reviewing recombinant DNA research conducted at the institution to ensure compliance with the NIH Guidelines.
Adopting emergency plans covering accidental spills and personnel contamination resulting from recombinant DNA research. Note: The Laboratory Safety Monograph describes basic elements for developing specific procedures dealing with major spills of potentially hazardous materials in the laboratory, including information and references about decontamination and emergency plans. The NIH and the Centers for Disease Control and Prevention are available to provide consultation and direct assistance, if necessary, as posted in the Laboratory Safety Monograph. The institution shall cooperate with the state and local public health departments by reporting any significant research-related illness or accident that may be hazardous to the public health.
Reporting any significant problems with or violations of the NIH Guidelines and any significant research related accidents or illnesses to the appropriate institutional official and NIH/OBA within 30 days, unless the Institutional Biosafety Committee determines that a report has already been filed by the Principal Investigator. Reports to NIH/OBA shall be sent to the Office of Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Suite 750, MSC 7985, Bethesda, MD 20892-7985 (20817 for non-USPS mail), 301-496-9838, 301-496-9839 (fax).
The Institutional Biosafety Committee may not authorize initiation of experiments which are not explicitly covered by the NIH Guidelines until NIH (with the advice of the RAC when required) establishes the containment requirement.
Performing such other functions as may be delegated to the Institutional Biosafety Committee under Section IV-B-2, Institutional Biosafety Committee.

Committee Members

Institutional Biosafety Committee Membership List (February 2017)

Committee Member Department
Doug Cyr, PhD Chair, Institutional Biosafety Committee and Professor, Cell & Development Biology
Victoria Baxter, DVM, PhD, DACLAM Assistant Professor, Division of Laboratory Animal Medicine
Sandra F. Bradshaw Laboratory Manager, Orange Water & Sewer Authority
Peggy Cotter, PhD Professor, Medicine, Microbiology and Immunology
Aravinda Desilva Professor, Medicine, Microbiology and Immunology
Craig Fletcher, DVM, PhD, DACLAM Director, Division of Laboratory Animal Medicine
Mary Beth Koza, MBA Director, Environment, Health and Safety
Stanley M. Lemon, PhD Professor, Medicine, Microbiology and Immunology
Ann Matthysse, PhD Professor, Department of Biology
Barry McLamb Emergency Management Coordinator, Town of Chapel Hill
Judith Nielsen, DVM Professor, Laboratory Animal Medicine
Jessica Poole, MS Interim Biological Safety Officer, Environment, Health and Safety
Barbara Savoldo, MD, PhD Research Professor, Pediatrics, Hematology and Oncology
Amy C. Sims, PhD Research Assistant Professor, Epidemiology
Dr. P. Frederick Sparling, MD Professor, Medicine, Microbiology and Immunology, Retired

High Containment Laboratory Subcommittee Membership List (May 2017)

Committee Member Department
Dr. Mark Heise Associate Professor, School of Medicine, Genetics; Co-Chair
Dr. Ralph Baric Professor, Epidemiology
Mark Bristol Life Safety and Access Superintendent, Building Services
Darius Dixon Executive Director of Facilities Operations
Greg Driver Director, Facilities Services, Engineering Services
Erika England Biological Safety Specialist
Craig Fletcher Director, Lab Animal Medicine
Dr. Victor Garcia-Martinez Professor, School of Medicine, Division of Infectious Diseases
Rob Kark Business Officer, School of Public Health
Mary Beth Koza Director, Environment, Health and Safety
Jeff McCracken Director, Public Safety
Katie O’Brien Strategic Communications Manager, School of Medicine
Jessica Poole Associate Biosafety Officer
Rod Rabold Commissioning Coordinator, Energy Management
William Roberson Project Manager

Committee Schedule

All meetings are held in Burnett-Womack room 9001.

2017 UNC Institutional Biosafety Committee Meetings

Date Time
December 14, 2016 3:30 p.m. – 5:00 p.m.
January 4, 2017 3:30 p.m. – 5:00 p.m.
February 1, 2017 3:30 p.m. – 5:00 p.m.
March 1, 2017 3:30 p.m. – 5:00 p.m.
April 5, 2017 3:30 p.m. – 5:00 p.m.
May 3, 2017 3:30 p.m. – 5:00 p.m.
June 7, 2017 3:30 p.m. – 5:00 p.m.
July 12, 2017 3:30 p.m. – 5:00 p.m.
August 2, 2017 3:30 p.m. – 5:00 p.m.
September 6, 2017 3:30 p.m. – 5:00 p.m.
October 4, 2017 3:30 p.m. – 5:00 p.m.
November 1, 2017 3:30 p.m. – 5:00 p.m.
December 6, 2017 3:30 p.m. – 5:00 p.m.